ERGIC2: A Potential Drug Target for Neurological Disorders (G51290)

Target Name: ERGIC2

NCBI ID: G51290

ERGIC2

Other Name(s): Erv41 | CDA14 | cd002 | Endoplasmic reticulum-Golgi intermediate compartment protein 2 | Cd002 | CD14 protein | ERGIC and golgi 2 | PTX1 | ERGI2_HUMAN

ERGIC2: A Potential Drug Target for Neurological Disorders

ERGIC2 (Erv41) is a protein that is expressed in various tissues throughout the body, including the brain, nervous system, and endocrine system. It is a member of the ERGIC (Endoplasmic Reticulum-associated G protein-coupled receptor) family, which is a large family of transmembrane proteins that play a critical role in intracellular signaling.

One of the functions of ERGIC2 is to regulate the levels of neurotransmitters, such as dopamine and serotonin, in the brain. It is thought to do this by interacting with the neurotransmitter receptors, which are located on the surface of the neurons.

ERGIC2 has also been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It is thought to be involved in the regulation of the levels of these neurotransmitters, as well as the formation of neurofibrillary tangles and the development of neurodegeneration.

In addition to its role in neurological disorders, ERGIC2 is also being investigated as a potential drug target. One of the reasons for this is that it is a relatively small protein, which makes it easier to target with small molecules. In addition, its expression is highly upregulated in certain tissues, which makes it more sensitive to drug treatment.

Currently, ERGIC2 is considered a drug target (or biomarker), especially in the nervous system. Its function is to regulate levels of neurotransmitters in the brain, such as dopamine and serotonin, by interacting with neurotransmitter receptors.

ERGIC2 has also been implicated in the development and progression of various neurological diseases, including Alzheimer's disease, Parkinson's disease and schizophrenia. It is thought to be involved in regulating the levels of these neurotransmitters and in the formation of neurofibrillary tangles and neurodegeneration.

In addition to its connection to neurological diseases, ERGIC2 has been considered a drug target because it is a relatively small protein, which makes it easier to bind to small molecules. Furthermore, its expression is highly upregulated in certain tissues, which makes it more likely to respond to drug treatments.

Protein Name: ERGIC And Golgi 2

Functions: Possible role in transport between endoplasmic reticulum and Golgi

The "ERGIC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERGIC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets